Fagron (ARSU.F) 주식 개요제약 조제 회사인 Fagron NV는 전 세계 병원, 약국, 클리닉 및 환자에게 개인 맞춤형 의약품을 제공합니다. 자세히 보기ARSU.F 펀더멘털 분석스노우플레이크 점수가치 평가4/6미래 성장1/6과거 실적4/6재무 건전성4/6배당3/6강점공정 가치 추정치보다 낮은 61.8% 에서 거래수익은 매년 13.5% 증가할 것으로 예상됩니다.지난 5년 동안 수입이 매년 9.1% 증가했습니다.위험 분석주식은 유동성이 매우 낮습니다불안정한 배당 실적부채비율이 높네요모든 위험 점검 보기ARSU.F Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$26.5315.1% 저평가 내재 할인율Growth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-25m1b2016201920222025202620282031Revenue €1.5bEarnings €142.5mAdvancedSet Fair ValueView all narrativesFagron NV 경쟁사Henry ScheinSymbol: NasdaqGS:HSICMarket cap: US$8.5bCardinal HealthSymbol: NYSE:CAHMarket cap: US$47.0bCencoraSymbol: NYSE:CORMarket cap: US$53.5bProgynySymbol: NasdaqGS:PGNYMarket cap: US$1.9b가격 이력 및 성과Fagron 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가€26.5352주 최고가€27.0052주 최저가€23.50베타0.381개월 변동0%3개월 변동-1.74%1년 변동n/a3년 변동n/a5년 변동17.66%IPO 이후 변동-51.38%최근 뉴스 및 업데이트공시 • May 13Fagron NV Approves Board AppointmentsFagron NV at its Annual and Extraordinary General Meeting of Shareholders held on May 11, 2026 confirmed the final appointments of Ms Ira Bindra as independent director and Mr. Philipp Klecka as non-executive director. Both had previously been appointed by the Board of Directors through co-optation.공시 • May 12Fagron NV Approves the Distribution of a Gross Dividend, Payable on 20 May 2026Fagron NV at its Annual and Extraordinary General Meeting of Shareholders held on May 11, 2026 approved the distribution of a gross dividend of EUR 0.40 per share. Ex-dividend date: 18 May 2026. Record date: 19 May 2026. Payment date: 20 May 2026.공시 • Feb 27Fagron NV (ENXTBR:FAGR) acquired Pharmavit Europe B.V. for €68 million.Fagron NV (ENXTBR:FAGR) acquired Pharmavit Europe B.V. for €68 million on February 26, 2026. A cash consideration of €68 million will be paid by Fagron NV. As part of consideration, €68 million is paid towards common equity of Pharmavit Europe B.V. For the period ending December 31, 2025, Pharmavit Europe B.V. reported total revenue of €62 million. Fagron NV (ENXTBR:FAGR) completed the acquisition of Pharmavit Europe B.V. on February 26, 2026.공시 • Jan 07Fagron NV (ENXTBR:FAGR) completed the acquisition of Gemini Industria De Insumos Farmaceuticos Ltda.Fagron NV (ENXTBR:FAGR) signed an agreement to acquire Gemini Industria De Insumos Farmaceuticos Ltda in a transaction with an enterprise value of BRL 250 million in the third quarter period ending September 30, 2024. The acquisition of Gemini Industria De Insumos Farmaceuticos (Purifarma) marking a significant milestone in cementing Fagron's market position in Brazil. Purifarma operates three facilities and employing around 180 people, Purifarma will integrate into Fagron’s infrastructure, driving synergies through increased operational leverage, procurement savings and an enhanced product portfolio. As of October 6, 2025, The Brazilian competition authority (CADE) approved the acquisition of Purifarma. Completion of the acquisition remains subject to customary closing conditions and completion of certain local corporate and contractual formalities. Augusto Cesar Barbosa de Souza and Leonardo Maniglia Duarte of Veirano Advogados acted as a legal advisor for Fagron NV. Augusto Hirata of Leite de Barros Zanin acted as a legal advisor for Gemini Industria De Insumos Farmaceuticos Ltda. Fagron NV (ENXTBR:FAGR) completed the acquisition of Gemini Industria De Insumos Farmaceuticos Ltda on January 6, 2026.공시 • Dec 21Fagron NV (ENXTBR:FAGR) acquired Amber Compounding Pharmacy Pte Ltd.Fagron NV (ENXTBR:FAGR) acquired Amber Compounding Pharmacy Pte Ltd on December 19, 2025. In a related transaction, Fagron NV is acquiring Vepakum. Fagron NV (ENXTBR:FAGR) completed the acquisition of Amber Compounding Pharmacy Pte Ltd on December 19, 2025.공시 • Nov 25Fagron NV (ENXTBR:FAGR) acquired Book of business from MAGILAB Korlatolt Felelossegu Tarsasag.Fagron NV (ENXTBR:FAGR) acquired Book of business from MAGILAB Korlatolt Felelossegu Tarsasag on November 24, 2025. In a related transaction, Fagron NV also acquired the book of business of AMARA. The combined purchase price of the two transactions amounts to approximately €26 million. Fagron NV (ENXTBR:FAGR) completed the acquisition of Book of business from MAGILAB Korlatolt Felelossegu Tarsasag on November 24, 2025.더 많은 업데이트 보기Recent updates공시 • May 13Fagron NV Approves Board AppointmentsFagron NV at its Annual and Extraordinary General Meeting of Shareholders held on May 11, 2026 confirmed the final appointments of Ms Ira Bindra as independent director and Mr. Philipp Klecka as non-executive director. Both had previously been appointed by the Board of Directors through co-optation.공시 • May 12Fagron NV Approves the Distribution of a Gross Dividend, Payable on 20 May 2026Fagron NV at its Annual and Extraordinary General Meeting of Shareholders held on May 11, 2026 approved the distribution of a gross dividend of EUR 0.40 per share. Ex-dividend date: 18 May 2026. Record date: 19 May 2026. Payment date: 20 May 2026.공시 • Feb 27Fagron NV (ENXTBR:FAGR) acquired Pharmavit Europe B.V. for €68 million.Fagron NV (ENXTBR:FAGR) acquired Pharmavit Europe B.V. for €68 million on February 26, 2026. A cash consideration of €68 million will be paid by Fagron NV. As part of consideration, €68 million is paid towards common equity of Pharmavit Europe B.V. For the period ending December 31, 2025, Pharmavit Europe B.V. reported total revenue of €62 million. Fagron NV (ENXTBR:FAGR) completed the acquisition of Pharmavit Europe B.V. on February 26, 2026.공시 • Jan 07Fagron NV (ENXTBR:FAGR) completed the acquisition of Gemini Industria De Insumos Farmaceuticos Ltda.Fagron NV (ENXTBR:FAGR) signed an agreement to acquire Gemini Industria De Insumos Farmaceuticos Ltda in a transaction with an enterprise value of BRL 250 million in the third quarter period ending September 30, 2024. The acquisition of Gemini Industria De Insumos Farmaceuticos (Purifarma) marking a significant milestone in cementing Fagron's market position in Brazil. Purifarma operates three facilities and employing around 180 people, Purifarma will integrate into Fagron’s infrastructure, driving synergies through increased operational leverage, procurement savings and an enhanced product portfolio. As of October 6, 2025, The Brazilian competition authority (CADE) approved the acquisition of Purifarma. Completion of the acquisition remains subject to customary closing conditions and completion of certain local corporate and contractual formalities. Augusto Cesar Barbosa de Souza and Leonardo Maniglia Duarte of Veirano Advogados acted as a legal advisor for Fagron NV. Augusto Hirata of Leite de Barros Zanin acted as a legal advisor for Gemini Industria De Insumos Farmaceuticos Ltda. Fagron NV (ENXTBR:FAGR) completed the acquisition of Gemini Industria De Insumos Farmaceuticos Ltda on January 6, 2026.공시 • Dec 21Fagron NV (ENXTBR:FAGR) acquired Amber Compounding Pharmacy Pte Ltd.Fagron NV (ENXTBR:FAGR) acquired Amber Compounding Pharmacy Pte Ltd on December 19, 2025. In a related transaction, Fagron NV is acquiring Vepakum. Fagron NV (ENXTBR:FAGR) completed the acquisition of Amber Compounding Pharmacy Pte Ltd on December 19, 2025.공시 • Nov 25Fagron NV (ENXTBR:FAGR) acquired Book of business from MAGILAB Korlatolt Felelossegu Tarsasag.Fagron NV (ENXTBR:FAGR) acquired Book of business from MAGILAB Korlatolt Felelossegu Tarsasag on November 24, 2025. In a related transaction, Fagron NV also acquired the book of business of AMARA. The combined purchase price of the two transactions amounts to approximately €26 million. Fagron NV (ENXTBR:FAGR) completed the acquisition of Book of business from MAGILAB Korlatolt Felelossegu Tarsasag on November 24, 2025.공시 • Nov 04Fagron NV, Annual General Meeting, May 11, 2026Fagron NV, Annual General Meeting, May 11, 2026.공시 • Oct 10Fagron NV Reaffirms Earnings Guidance for the Fiscal Year 2025Fagron NV reaffirmed earnings guidance for the fiscal year 2025. For the period, Company confirms revenue to be €930 million to €950 million and continue to expect a slight improvement in profitability year on year.공시 • Oct 09+ 1 more updateFagron NV to Report Fiscal Year 2025 Results on Feb 12, 2026Fagron NV announced that they will report fiscal year 2025 results on Feb 12, 2026공시 • Oct 06Fagron Receives Brazilian Antitrust Clearance for Purifarma and Injeplast AcquisitionsFagron announced that the Brazilian competition authority, CADE, has granted clearance for the previously announced acquisitions of Purifarma and Injeplast in Brazil. The clearances represent an important step forward in executing Fagron’s disciplined M&A strategy in Latin America. The transactions will broaden Fagron’s portfolio and capabilities in Brazil, supporting the Group’s ambition to build a scalable, high-quality platform aligned with its long-term growth objectives.Purifarma operates a highly concentrated Essentials portfolio at very large volumes, presenting significant potential to improve profitability within 18 months post-closing through enhanced product portfolio and brands expansion, as well as increased operational leverage and procurement savings. In addition, the scale-up is expected to generate procurement benefits not only across Latin America but throughout our entire global footprint. Injeplast will further strengthen Fagron’s vertical integration by producing high-quality packaging solutions and efficient manufacturing processes, supporting our Essentials strategy by broadening our product portfolio and customer base in Latin America as well as other regions. Completion of the acquisitions remains subject to customary closing conditions and completion of certain local corporate and contractual formalities.공시 • Sep 26Fagron NV (ENXTBR:FAGR) agreed to acquire University Rx Specialists, Inc. at an enterprise value of CAD 41.5 million.Fagron NV (ENXTBR:FAGR) agreed to acquire University Rx Specialists, Inc. at an enterprise value of CAD 41.5 million on September 25, 2025. UCP generates around twenty five million dollars in annual revenue. The transaction will be fully financed through Fagron’s own resources and remains subject to customary clearance.공시 • Apr 11Fagron NV (ENXTBR:FAGR) completed the acquisition of Carefirst Specialty Pharmacy LLC.Fagron NV (ENXTBR:FAGR) agreed to acquire Carefirst Specialty Pharmacy LLC on January 7, 2025. In a related transaction, Fagron signed an agreement to acquire Injeplast on January 7, 2025. The combined enterprise value of these two acquisitions is €30 million and are fully financed through Fagron’s own resources and remain subject to customary clearances. Both businesses operate with an EBITDA margin slightly above Fagron’s existing group margin. Fagron NV (ENXTBR:FAGR) completed the acquisition of Carefirst Specialty Pharmacy LLC on April 10, 2025.공시 • Feb 22+ 1 more updateFagron NV Provides Earnings Guidance for the Year 2025Fagron NV provided earnings guidance for the year 2025. Full year 2025 outlook of mid- to high-single digit organic sales growth and slight improvement in profitability year on year, at CER and a slight improvement in profitability year-on-year, weighted towards the second half of the year.공시 • Feb 05Fagron NV (ENXTBR:FAGR) agreed to acquire Guinama, S.L.U. for an enterprise value of €22 million.Fagron NV (ENXTBR:FAGR) agreed to acquire Guinama, S.L.U. for an enterprise value of €22 million on February 4, 2025. The acquisition will close on signing.공시 • Jan 08Fagron NV, Annual General Meeting, May 12, 2025Fagron NV, Annual General Meeting, May 12, 2025.공시 • Jan 07+ 4 more updatesFagron NV (ENXTBR:FAGR) agreed to acquire Carefirst Specialty Pharmacy LLC.Fagron NV (ENXTBR:FAGR) agreed to acquire Carefirst Specialty Pharmacy LLC on January 7, 2025. In a related transaction, Fagron signed an agreement to acquire Injeplast on January 7, 2025. The combined enterprise value of these two acquisitions is €30 million and are fully financed through Fagron’s own resources and remain subject to customary clearances. Both businesses operate with an EBITDA margin slightly above Fagron’s existing group margin.공시 • Oct 11Fagron NV (ENXTBR:FAGR) ) signed an agreement to acquire Euro OTC Pharma GmbH.Fagron NV (ENXTBR:FAGR) ) signed an agreement to acquire Euro OTC Pharma GmbH in the third quarter period ending September 30, 2024. Acquisition of EuroOTC raw materials will enhance our presence in Germany, creating synergies through increased scale and enhanced customer engagement.공시 • Oct 10Fagron NV Reaffirms Earnings Guidance for the Full Year 2024Fagron NV reaffirmed earnings guidance for the full year 2024. Maintain Full Year 2024 revenue outlook of €850 million to €870 million and improvement in profitability year-on-year.공시 • May 15Fagron NV Approves Dividend for the Year 2023, Payable on 23 May 2024The annual general meeting approved, amongst other things, Fagron’s annual financial statements and dividend proposal of €0.30 per share for the fiscal year 2023, and the remuneration policy. Ex-dividend date: 21 May 2024. Record date: 22 May 2024. Payment date: 23 May 2024.공시 • Apr 11Fagron Provides Earnings Guidance for the Fiscal Year 2024Fagron provided earnings guidance for the fiscal year 2024. For the year, the company expects high single-digit organic sales growth and improvement in profitability reaffirmed.공시 • Feb 16Fagron NV, Annual General Meeting, May 13, 2024Fagron NV, Annual General Meeting, May 13, 2024.공시 • Feb 15+ 1 more updateFagron NV Provides Earnings Guidance for the Full Year 2024Fagron NV provided earnings guidance for the full year 2024. For the period, Company expects high single-digit organic revenue growth and continued improvement in profitability.공시 • Oct 13Fagron Nv Provides Earnings Guidance for 2023Fagron NV provided earnings guidance for 2023. For full year revenue guidance, The company expects a EUR 750 million to EUR 770 million range. On profitability, the company reiterate guidance of year-on-year increase.공시 • Oct 12+ 1 more updateFagron NV to Report First Half, 2024 Results on Aug 01, 2024Fagron NV announced that they will report first half, 2024 results on Aug 01, 2024공시 • May 10+ 1 more updateFagron Nv Announces Board ChangesFagron NV at the annual general meeting of shareholders held on 8 May 2023, approved the stepping down of Management Deprez BV, represented by Veerle Deprez and approved appointment of Els Vandecandelaere LLC, represented by Klaus Röhrig.공시 • Feb 09Fagron Nv Proposes DividendFagron NV proposed Dividend of €0.25 per share.공시 • Feb 05+ 2 more updatesFagron NV to Report Fiscal Year 2022 Results on Feb 09, 2023Fagron NV announced that they will report fiscal year 2022 results on Feb 09, 2023주주 수익률ARSU.FUS HealthcareUS 시장7D0%-0.4%1.1%1Yn/a16.3%28.7%전체 주주 수익률 보기수익률 대 산업: ARSU.F의 US Healthcare 산업 대비 성과를 판단하기에 데이터가 부족합니다.수익률 대 시장: ARSU.F의 US 시장 대비 성과를 판단하기에 데이터가 부족합니다.주가 변동성Is ARSU.F's price volatile compared to industry and market?ARSU.F volatilityARSU.F Average Weekly Movementn/aHealthcare Industry Average Movement7.6%Market Average Movement7.2%10% most volatile stocks in US Market16.5%10% least volatile stocks in US Market3.1%안정적인 주가: ARSU.F의 주가는 지난 3개월 동안 US 시장보다 변동성이 컸습니다.시간에 따른 변동성: Insufficient data to determine ARSU.F의 변동성 변화를 판단할 수 없습니다.회사 소개설립직원 수CEO웹사이트19904,193Rafael Padillawww.fagron.com제약 조제 회사인 Fagron NV는 전 세계 병원, 약국, 클리닉 및 환자에게 맞춤형 의약품을 제공합니다. 이 회사는 세 가지 부문으로 운영됩니다: 에센셜, 브랜드, 컴파운딩 서비스입니다. 또한 제약 컴파운딩을 위한 개념, 수단 및 제형도 혁신하고 있습니다.더 보기Fagron NV 기초 지표 요약Fagron의 순이익과 매출은 시가총액과 어떻게 비교됩니까?ARSU.F 기초 통계시가총액US$2.13b순이익 (TTM)US$105.64m매출 (TTM)US$1.11b20.1x주가수익비율(P/E)1.9x주가매출비율(P/S)ARSU.F는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표ARSU.F 손익계산서 (TTM)매출€952.17m매출원가€520.16m총이익€432.01m기타 비용€340.99m순이익€91.02m최근 보고된 실적Dec 31, 2025다음 실적 발표일Jul 30, 2026주당순이익(EPS)1.24총이익률45.37%순이익률9.56%부채/자본 비율74.3%ARSU.F의 장기 실적은 어땠습니까?과거 실적 및 비교 보기배당1.6%현재 배당 수익률32%배당 성향View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/23 15:18종가2026/04/10 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Fagron NV는 13명의 분석가가 다루고 있습니다. 이 중 5명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Beatrice FairbairnBerenbergSamuel EnglandBerenbergBeatrice AllenBerenberg10명의 분석가 더 보기
공시 • May 13Fagron NV Approves Board AppointmentsFagron NV at its Annual and Extraordinary General Meeting of Shareholders held on May 11, 2026 confirmed the final appointments of Ms Ira Bindra as independent director and Mr. Philipp Klecka as non-executive director. Both had previously been appointed by the Board of Directors through co-optation.
공시 • May 12Fagron NV Approves the Distribution of a Gross Dividend, Payable on 20 May 2026Fagron NV at its Annual and Extraordinary General Meeting of Shareholders held on May 11, 2026 approved the distribution of a gross dividend of EUR 0.40 per share. Ex-dividend date: 18 May 2026. Record date: 19 May 2026. Payment date: 20 May 2026.
공시 • Feb 27Fagron NV (ENXTBR:FAGR) acquired Pharmavit Europe B.V. for €68 million.Fagron NV (ENXTBR:FAGR) acquired Pharmavit Europe B.V. for €68 million on February 26, 2026. A cash consideration of €68 million will be paid by Fagron NV. As part of consideration, €68 million is paid towards common equity of Pharmavit Europe B.V. For the period ending December 31, 2025, Pharmavit Europe B.V. reported total revenue of €62 million. Fagron NV (ENXTBR:FAGR) completed the acquisition of Pharmavit Europe B.V. on February 26, 2026.
공시 • Jan 07Fagron NV (ENXTBR:FAGR) completed the acquisition of Gemini Industria De Insumos Farmaceuticos Ltda.Fagron NV (ENXTBR:FAGR) signed an agreement to acquire Gemini Industria De Insumos Farmaceuticos Ltda in a transaction with an enterprise value of BRL 250 million in the third quarter period ending September 30, 2024. The acquisition of Gemini Industria De Insumos Farmaceuticos (Purifarma) marking a significant milestone in cementing Fagron's market position in Brazil. Purifarma operates three facilities and employing around 180 people, Purifarma will integrate into Fagron’s infrastructure, driving synergies through increased operational leverage, procurement savings and an enhanced product portfolio. As of October 6, 2025, The Brazilian competition authority (CADE) approved the acquisition of Purifarma. Completion of the acquisition remains subject to customary closing conditions and completion of certain local corporate and contractual formalities. Augusto Cesar Barbosa de Souza and Leonardo Maniglia Duarte of Veirano Advogados acted as a legal advisor for Fagron NV. Augusto Hirata of Leite de Barros Zanin acted as a legal advisor for Gemini Industria De Insumos Farmaceuticos Ltda. Fagron NV (ENXTBR:FAGR) completed the acquisition of Gemini Industria De Insumos Farmaceuticos Ltda on January 6, 2026.
공시 • Dec 21Fagron NV (ENXTBR:FAGR) acquired Amber Compounding Pharmacy Pte Ltd.Fagron NV (ENXTBR:FAGR) acquired Amber Compounding Pharmacy Pte Ltd on December 19, 2025. In a related transaction, Fagron NV is acquiring Vepakum. Fagron NV (ENXTBR:FAGR) completed the acquisition of Amber Compounding Pharmacy Pte Ltd on December 19, 2025.
공시 • Nov 25Fagron NV (ENXTBR:FAGR) acquired Book of business from MAGILAB Korlatolt Felelossegu Tarsasag.Fagron NV (ENXTBR:FAGR) acquired Book of business from MAGILAB Korlatolt Felelossegu Tarsasag on November 24, 2025. In a related transaction, Fagron NV also acquired the book of business of AMARA. The combined purchase price of the two transactions amounts to approximately €26 million. Fagron NV (ENXTBR:FAGR) completed the acquisition of Book of business from MAGILAB Korlatolt Felelossegu Tarsasag on November 24, 2025.
공시 • May 13Fagron NV Approves Board AppointmentsFagron NV at its Annual and Extraordinary General Meeting of Shareholders held on May 11, 2026 confirmed the final appointments of Ms Ira Bindra as independent director and Mr. Philipp Klecka as non-executive director. Both had previously been appointed by the Board of Directors through co-optation.
공시 • May 12Fagron NV Approves the Distribution of a Gross Dividend, Payable on 20 May 2026Fagron NV at its Annual and Extraordinary General Meeting of Shareholders held on May 11, 2026 approved the distribution of a gross dividend of EUR 0.40 per share. Ex-dividend date: 18 May 2026. Record date: 19 May 2026. Payment date: 20 May 2026.
공시 • Feb 27Fagron NV (ENXTBR:FAGR) acquired Pharmavit Europe B.V. for €68 million.Fagron NV (ENXTBR:FAGR) acquired Pharmavit Europe B.V. for €68 million on February 26, 2026. A cash consideration of €68 million will be paid by Fagron NV. As part of consideration, €68 million is paid towards common equity of Pharmavit Europe B.V. For the period ending December 31, 2025, Pharmavit Europe B.V. reported total revenue of €62 million. Fagron NV (ENXTBR:FAGR) completed the acquisition of Pharmavit Europe B.V. on February 26, 2026.
공시 • Jan 07Fagron NV (ENXTBR:FAGR) completed the acquisition of Gemini Industria De Insumos Farmaceuticos Ltda.Fagron NV (ENXTBR:FAGR) signed an agreement to acquire Gemini Industria De Insumos Farmaceuticos Ltda in a transaction with an enterprise value of BRL 250 million in the third quarter period ending September 30, 2024. The acquisition of Gemini Industria De Insumos Farmaceuticos (Purifarma) marking a significant milestone in cementing Fagron's market position in Brazil. Purifarma operates three facilities and employing around 180 people, Purifarma will integrate into Fagron’s infrastructure, driving synergies through increased operational leverage, procurement savings and an enhanced product portfolio. As of October 6, 2025, The Brazilian competition authority (CADE) approved the acquisition of Purifarma. Completion of the acquisition remains subject to customary closing conditions and completion of certain local corporate and contractual formalities. Augusto Cesar Barbosa de Souza and Leonardo Maniglia Duarte of Veirano Advogados acted as a legal advisor for Fagron NV. Augusto Hirata of Leite de Barros Zanin acted as a legal advisor for Gemini Industria De Insumos Farmaceuticos Ltda. Fagron NV (ENXTBR:FAGR) completed the acquisition of Gemini Industria De Insumos Farmaceuticos Ltda on January 6, 2026.
공시 • Dec 21Fagron NV (ENXTBR:FAGR) acquired Amber Compounding Pharmacy Pte Ltd.Fagron NV (ENXTBR:FAGR) acquired Amber Compounding Pharmacy Pte Ltd on December 19, 2025. In a related transaction, Fagron NV is acquiring Vepakum. Fagron NV (ENXTBR:FAGR) completed the acquisition of Amber Compounding Pharmacy Pte Ltd on December 19, 2025.
공시 • Nov 25Fagron NV (ENXTBR:FAGR) acquired Book of business from MAGILAB Korlatolt Felelossegu Tarsasag.Fagron NV (ENXTBR:FAGR) acquired Book of business from MAGILAB Korlatolt Felelossegu Tarsasag on November 24, 2025. In a related transaction, Fagron NV also acquired the book of business of AMARA. The combined purchase price of the two transactions amounts to approximately €26 million. Fagron NV (ENXTBR:FAGR) completed the acquisition of Book of business from MAGILAB Korlatolt Felelossegu Tarsasag on November 24, 2025.
공시 • Nov 04Fagron NV, Annual General Meeting, May 11, 2026Fagron NV, Annual General Meeting, May 11, 2026.
공시 • Oct 10Fagron NV Reaffirms Earnings Guidance for the Fiscal Year 2025Fagron NV reaffirmed earnings guidance for the fiscal year 2025. For the period, Company confirms revenue to be €930 million to €950 million and continue to expect a slight improvement in profitability year on year.
공시 • Oct 09+ 1 more updateFagron NV to Report Fiscal Year 2025 Results on Feb 12, 2026Fagron NV announced that they will report fiscal year 2025 results on Feb 12, 2026
공시 • Oct 06Fagron Receives Brazilian Antitrust Clearance for Purifarma and Injeplast AcquisitionsFagron announced that the Brazilian competition authority, CADE, has granted clearance for the previously announced acquisitions of Purifarma and Injeplast in Brazil. The clearances represent an important step forward in executing Fagron’s disciplined M&A strategy in Latin America. The transactions will broaden Fagron’s portfolio and capabilities in Brazil, supporting the Group’s ambition to build a scalable, high-quality platform aligned with its long-term growth objectives.Purifarma operates a highly concentrated Essentials portfolio at very large volumes, presenting significant potential to improve profitability within 18 months post-closing through enhanced product portfolio and brands expansion, as well as increased operational leverage and procurement savings. In addition, the scale-up is expected to generate procurement benefits not only across Latin America but throughout our entire global footprint. Injeplast will further strengthen Fagron’s vertical integration by producing high-quality packaging solutions and efficient manufacturing processes, supporting our Essentials strategy by broadening our product portfolio and customer base in Latin America as well as other regions. Completion of the acquisitions remains subject to customary closing conditions and completion of certain local corporate and contractual formalities.
공시 • Sep 26Fagron NV (ENXTBR:FAGR) agreed to acquire University Rx Specialists, Inc. at an enterprise value of CAD 41.5 million.Fagron NV (ENXTBR:FAGR) agreed to acquire University Rx Specialists, Inc. at an enterprise value of CAD 41.5 million on September 25, 2025. UCP generates around twenty five million dollars in annual revenue. The transaction will be fully financed through Fagron’s own resources and remains subject to customary clearance.
공시 • Apr 11Fagron NV (ENXTBR:FAGR) completed the acquisition of Carefirst Specialty Pharmacy LLC.Fagron NV (ENXTBR:FAGR) agreed to acquire Carefirst Specialty Pharmacy LLC on January 7, 2025. In a related transaction, Fagron signed an agreement to acquire Injeplast on January 7, 2025. The combined enterprise value of these two acquisitions is €30 million and are fully financed through Fagron’s own resources and remain subject to customary clearances. Both businesses operate with an EBITDA margin slightly above Fagron’s existing group margin. Fagron NV (ENXTBR:FAGR) completed the acquisition of Carefirst Specialty Pharmacy LLC on April 10, 2025.
공시 • Feb 22+ 1 more updateFagron NV Provides Earnings Guidance for the Year 2025Fagron NV provided earnings guidance for the year 2025. Full year 2025 outlook of mid- to high-single digit organic sales growth and slight improvement in profitability year on year, at CER and a slight improvement in profitability year-on-year, weighted towards the second half of the year.
공시 • Feb 05Fagron NV (ENXTBR:FAGR) agreed to acquire Guinama, S.L.U. for an enterprise value of €22 million.Fagron NV (ENXTBR:FAGR) agreed to acquire Guinama, S.L.U. for an enterprise value of €22 million on February 4, 2025. The acquisition will close on signing.
공시 • Jan 08Fagron NV, Annual General Meeting, May 12, 2025Fagron NV, Annual General Meeting, May 12, 2025.
공시 • Jan 07+ 4 more updatesFagron NV (ENXTBR:FAGR) agreed to acquire Carefirst Specialty Pharmacy LLC.Fagron NV (ENXTBR:FAGR) agreed to acquire Carefirst Specialty Pharmacy LLC on January 7, 2025. In a related transaction, Fagron signed an agreement to acquire Injeplast on January 7, 2025. The combined enterprise value of these two acquisitions is €30 million and are fully financed through Fagron’s own resources and remain subject to customary clearances. Both businesses operate with an EBITDA margin slightly above Fagron’s existing group margin.
공시 • Oct 11Fagron NV (ENXTBR:FAGR) ) signed an agreement to acquire Euro OTC Pharma GmbH.Fagron NV (ENXTBR:FAGR) ) signed an agreement to acquire Euro OTC Pharma GmbH in the third quarter period ending September 30, 2024. Acquisition of EuroOTC raw materials will enhance our presence in Germany, creating synergies through increased scale and enhanced customer engagement.
공시 • Oct 10Fagron NV Reaffirms Earnings Guidance for the Full Year 2024Fagron NV reaffirmed earnings guidance for the full year 2024. Maintain Full Year 2024 revenue outlook of €850 million to €870 million and improvement in profitability year-on-year.
공시 • May 15Fagron NV Approves Dividend for the Year 2023, Payable on 23 May 2024The annual general meeting approved, amongst other things, Fagron’s annual financial statements and dividend proposal of €0.30 per share for the fiscal year 2023, and the remuneration policy. Ex-dividend date: 21 May 2024. Record date: 22 May 2024. Payment date: 23 May 2024.
공시 • Apr 11Fagron Provides Earnings Guidance for the Fiscal Year 2024Fagron provided earnings guidance for the fiscal year 2024. For the year, the company expects high single-digit organic sales growth and improvement in profitability reaffirmed.
공시 • Feb 16Fagron NV, Annual General Meeting, May 13, 2024Fagron NV, Annual General Meeting, May 13, 2024.
공시 • Feb 15+ 1 more updateFagron NV Provides Earnings Guidance for the Full Year 2024Fagron NV provided earnings guidance for the full year 2024. For the period, Company expects high single-digit organic revenue growth and continued improvement in profitability.
공시 • Oct 13Fagron Nv Provides Earnings Guidance for 2023Fagron NV provided earnings guidance for 2023. For full year revenue guidance, The company expects a EUR 750 million to EUR 770 million range. On profitability, the company reiterate guidance of year-on-year increase.
공시 • Oct 12+ 1 more updateFagron NV to Report First Half, 2024 Results on Aug 01, 2024Fagron NV announced that they will report first half, 2024 results on Aug 01, 2024
공시 • May 10+ 1 more updateFagron Nv Announces Board ChangesFagron NV at the annual general meeting of shareholders held on 8 May 2023, approved the stepping down of Management Deprez BV, represented by Veerle Deprez and approved appointment of Els Vandecandelaere LLC, represented by Klaus Röhrig.
공시 • Feb 05+ 2 more updatesFagron NV to Report Fiscal Year 2022 Results on Feb 09, 2023Fagron NV announced that they will report fiscal year 2022 results on Feb 09, 2023
